By Gary M. White, MD

Ixekizumab (brand name Taltz) is a monoclonal antibody that targets interleukin-17A and is highly effective in the treatment of psoriasis.


Ixekizumab is indicated for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dosage and Administration

Administer by subcutaneous injection. The recommended dose is 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.

Warnings and Precautions

Adverse Reactions

Most common (≥1%) adverse reactions associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.


Live vaccines should not be given during therapy with ixekizumab.


Homepage | FAQs | Use of Images | Contact Dr. White

It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.